Research Analysts Issue Forecasts for RAPT Therapeutics, Inc.’s Q1 2023 Earnings (NASDAQ:RAPT)

RAPT Therapeutics, Inc. (NASDAQ:RAPT – Get Rating) – Investment analysts at Capital One Financial issued their Q1 2023 EPS estimates for shares of RAPT Therapeutics in a research note issued on Wednesday, March 15th. Capital One Financial analyst Z. Jallah expects that the company will post earnings of ($0.51) per share for the quarter. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.86) per share. Capital One Financial also issued estimates for RAPT Therapeutics’ Q2 2023 earnings at ($0.54) EPS, Q3 2023 earnings at ($0.57) EPS, Q4 2023 earnings at ($0.54) EPS, FY2023 earnings at ($2.17) EPS, FY2024 earnings at ($2.70) EPS, FY2025 earnings at ($3.45) EPS, FY2026 earnings at $0.72 EPS and FY2027 earnings at $10.26 EPS.

Several other research analysts also recently weighed in on RAPT. The Goldman Sachs Group dropped their target price on shares of RAPT Therapeutics from $27.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright dropped their target price on shares of RAPT Therapeutics from $50.00 to $43.00 and set a “buy” rating for the company in a report on Wednesday. Wells Fargo & Company dropped their target price on shares of RAPT Therapeutics from $55.00 to $48.00 and set an “overweight” rating for the company in a report on Wednesday, January 4th. Piper Sandler dropped their target price on shares of RAPT Therapeutics from $34.00 to $33.00 in a report on Thursday, December 8th. Finally, Cantor Fitzgerald dropped their target price on shares of RAPT Therapeutics from $44.00 to $40.00 in a report on Wednesday. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $41.38.

RAPT Therapeutics Stock Performance

Shares of RAPT Therapeutics stock opened at $18.94 on Friday. The company has a market capitalization of $649.45 million, a P/E ratio of -7.34 and a beta of 0.46. The company has a fifty day moving average of $27.10 and a 200 day moving average of $23.28. RAPT Therapeutics has a fifty-two week low of $9.85 and a fifty-two week high of $32.45.

Insiders Place Their Bets

In related news, Director Wendye Robbins purchased 2,500 shares of the firm’s stock in a transaction on Tuesday, March 14th. The shares were acquired at an average price of $18.99 per share, for a total transaction of $47,475.00. Following the purchase, the director now directly owns 14,900 shares in the company, valued at $282,951. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In related news, insider William Ho sold 5,000 shares of RAPT Therapeutics stock in a transaction dated Thursday, December 29th. The stock was sold at an average price of $18.03, for a total value of $90,150.00. Following the completion of the transaction, the insider now owns 37,650 shares in the company, valued at $678,829.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Wendye Robbins acquired 2,500 shares of RAPT Therapeutics stock in a transaction on Tuesday, March 14th. The shares were bought at an average cost of $18.99 per share, for a total transaction of $47,475.00. Following the completion of the purchase, the director now directly owns 14,900 shares of the company’s stock, valued at $282,951. The disclosure for this purchase can be found here. Insiders have sold a total of 20,742 shares of company stock worth $532,352 in the last 90 days. 5.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On RAPT Therapeutics

Institutional investors have recently modified their holdings of the stock. Swiss National Bank increased its position in shares of RAPT Therapeutics by 7.6% during the 1st quarter. Swiss National Bank now owns 45,400 shares of the company’s stock valued at $998,000 after purchasing an additional 3,200 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of RAPT Therapeutics by 23.7% during the 1st quarter. JPMorgan Chase & Co. now owns 13,575 shares of the company’s stock valued at $299,000 after purchasing an additional 2,599 shares during the last quarter. MetLife Investment Management LLC increased its position in shares of RAPT Therapeutics by 58.5% during the 1st quarter. MetLife Investment Management LLC now owns 11,028 shares of the company’s stock valued at $243,000 after purchasing an additional 4,070 shares during the last quarter. Rhumbline Advisers increased its position in shares of RAPT Therapeutics by 18.3% during the 1st quarter. Rhumbline Advisers now owns 21,961 shares of the company’s stock valued at $483,000 after purchasing an additional 3,405 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of RAPT Therapeutics by 32.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 285,325 shares of the company’s stock valued at $6,274,000 after purchasing an additional 69,238 shares during the last quarter.

RAPT Therapeutics Company Profile

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.